SEC Filings

DPW HOLDINGS, INC. filed this Form 8-K on 02/25/2019
Entire Document

CAO 22 W Alzamend ™ □ Our goal is to develop a safer and better Alzheimer’s Abeta vaccine candidate that will be devoid of the problems associated wit h current vaccine therapy. Our studies concluded the successful vaccination of mice with adjuvant - free mutated Abeta peptides have signifi cant advantages over both native Abeta and the use of adjuvant. □ 10 weeks old female BALB/c mice were housed in Varian standard cages including amber igloos and vaccinated when 14 weeks old. □ Differently mutated Abeta 1 - 42 peptides were used for each group and a 1.times.PBS (also containing 10% DMSO) as a control group . The Results: □ Mice vaccinated with various mutated Abeta 1 - 42 peptides induce antibody responses after two inoculations, while no antibody can be detected in the control group (FIG. 5 A). □ All antibodies induced by the peptide injection bind to the same epitope. There is no difference in recognition between the various anti - sera and peptides such that all anti - sera recognize the 1 - 16 epitope on all peptides. □ Demonstrate definite advantages over previous vaccination protocols, which strongly support our Adjuvant - Free Vaccine Hypothesis. □ The data clearly show that wild type and mutated amyloid beta peptide administrated without adjuvant induce a strong and long lasting antibody response. □ The first use of adjuvant - free Abeta as Alzheimer's vaccines and demonstrate that T cell epitope mutation will contribute to either Th 1 or Th 2 response. Those peptides will have an outstanding promise for the treatment of Alzheimer's disease. Alzamend Neuro, Inc. Information cannot be disclosed or reprinted without prior written permission from Alzamend Neuro, Inc . February 2019 119